Royalty Pharma (RPRX) FCF Margin Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) FCF Margin Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9,545.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -7.75 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -3,088.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4,612.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 14,060.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,088.00 |
| Mar 31, 2026 | -2,102.00 |
| Dec 31, 2025 | -4,148.00 |
| Sep 30, 2025 | 9,303.00 |
| Jun 30, 2025 | -1,191.00 |
| Mar 31, 2025 | 2,284.00 |
| Dec 31, 2024 | -1,382.00 |
| Sep 30, 2024 | 6,094.00 |
| Jun 30, 2024 | -7,636.00 |
| Mar 31, 2024 | 9,784.00 |
| Dec 31, 2023 | 334.00 |
| Sep 30, 2023 | 7,736.00 |
| Jun 30, 2023 | 9,903.00 |
| Mar 31, 2023 | -1,105.00 |
| Dec 31, 2022 | 5,396.00 |
| Sep 30, 2022 | -22,092.00 |